Objective: The design of this study was due to the report of the antioxidant properties of Ellagic acid (EA) for its evaluation on the Insulin resistance (IR), oxidative stress and sex hormones levels in women with polycystic ovarian syndrome (PCOS). Methods: In this randomized, double-blind, placebo-controlled clinical trial, 60 patients were recruited. Patients were randomly allocated consumed a capsule containing 200 mg of EA per day (n = 30) or placebo (n = 30) for 8 weeks. The fasting blood sugar (FBS), insulin, IR, total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL), high density lipoprotein (HDL), total antioxidant capacity (TAC), Malondialdehyde (MDA), C-reactive protein (CRP), Tumor necrosis factor-alpha (TNF-α), sex hormones and anti-mullerian hormone (AMH) were measured at the beginning and end of the study. Result: At the end of the study, the mean of FBS, insulin, IR, TC, TG, LDL, MDA, CRP, TNF-α, total testosterone, prolactin and AMH were significantly decreased in the intervention group compared to the placebo group (P < 0.05). Also, there was a significant increase in the mean of TAC after supplementation with EA (P < 0.05). At the end of the study, no significant changes were observed in the mean of anthropometric factors, physical activity and food intake (P > 0.05). Conclusion: EA supplementation can be helpful as a diet supplement in women with PCOS through improvement in insulin resistance. This supplement may be used to reduce metabolic disorders in women. Trial registration: This study was retrospectively (07–07-2019) registered in the Iranian website (www.irct.ir) for registration of clinical trials (IRCT20141025019669N12).
1 April 2021 in Journal of Gynecology Obstetrics and Human Reproduction
Background. Myopathy is one of the side effects of lipid-lowering drugs, especially statins and particularly when combined with a fibrate. To diagnose myopathy and determine its severity, the plasma levels of three enzymes, creatine kinase (CK), aldolase, and lactate dehydrogenase (LDH), are routinely measured. Physical exercise can aggravate the statin-associated muscular disease. The question is whether antioxidants like ascorbic acid (Vit. C) can prevent such myopathy. Methods. In this experiment, a combination of atorvastatin (ATV, 80 mg/kg/day) and gemfibrozil (GMF, 1000 mg/kg/day) orally for 10 days as well as exercise as forced swimming on days 8, 9, and 10 were used to induce myopathy. Ascorbic acid (50 mg/kg/day, orally) was added to ATV/GMF plus exercise regimen throughout the 10 days in the treatment group. Mean blood levels of CK, aldolase, and LDH were measured in addition to swimming tolerance times. Results. There was a significantly higher swimming tolerance time and lower CK levels in rats receiving ATV/GMF/Vit. C plus exercise compared with rats not taking Vit. C. LDH and aldolase did not decrease significantly. Conclusion. The results of this study showed that Vit. C can be effective in preventing myopathy caused by fat-lowering drugs.
31 August 2016 in Jundishapur Journal of Natural Pharmaceutical Products
Background: Pulmonary fibrosis is an idiopathic and chronic inflammatory interstitial lung disease that responds only weakly to available medical therapies and has a potentially fatal prognosis. Hibiscus sabdariffa L. contains several antioxidants, such as protocatechuic acid (PCA) and anthocyanins, which may be beneficial for the treatment of fibrosis. Objectives: The purpose of this study was to investigate the inhibitory effect of the H. sabdariffa L. extract (HSE) on angiotensin-converting enzyme (ACE) and compare it with that of enalapril in a rat model of bleomycin-induced pulmonary fibrosis. Methods: Female Wistar rats (weighing 180 g- 235 g) were randomly divided into seven groups (n = 8). The negative and positive control groups were intratracheally administered a single dose of saline (1 mL/kg) and bleomycin (7.5 UI/kg/mL) respectively. The treatment groups were orally administered enalapril (20 mg/kg), PCA (100 mg/kg) and HSE (100, 200, and 400 mg/kg) daily for one week before and three weeks after bleomycin administration. The animals were sacrificed 24 hours after the last administration of the therapeutic agent. The transforming growth factor-β1, platelet-derived growth factor, tumor necrosis factor-α and angiotensin II (ANG II) levels in the bronchoalveolar lavage fluid (BALF) and also the malondialdehyde (MDA) and hydroxyproline (HP) levels in lung tissue were measured. The presence of fibrosis, inflammatory cells, connective tissue and collagen deposition in the lung was microscopically evaluated using Masson’s trichrome staining. Results: The results showed a significant increase in the lung index and the levels of MDA, HP, ANG II and pro-inflammatory cytokines after bleomycin administration. Pre-treatment with enalapril, PCA and HSE resulted in a reduction in the levels of the above factors. Enalapril and HSE (400 mg/kg) treatment could mitigate the progression of fibrosis clearly via ACE blocking and a decrease in the level of oxidative stress. Enalapril, PCA and HSE could prevent the infiltration of fibroblasts, inflammatory cells and alveolar thickening caused by bleomycin. Conclusions: Our results indicate that HSE, which has demonstrated anti-hypertensive effects in herbal medicine, can be useful for the treatment of inflammatory and fibrotic disorders. Keywords: Hibiscus sabdariffa; Bleomycin; Enalapril; Pulmonary Fibrosis; Protocatechuic Acid; Rat